A Phase 1 interventional study of RO6867461 in Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 8 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.
Among the 14 studies testing faricimab in Macular Degeneration, this one is the 14th largest by enrollment, is the only one that started in 2013, is the only one in phase 1, and was the 1st registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:
Junyeop Lee · Sites in Korea, Republic of
Ages 50+
Biobizkaia Health Research Institute · Sites in Spain
Ages 50+
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 50+
Singapore National Eye Centre · Sites in Singapore
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
By country, each count listing its studies:
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2013; this study’s year is marked. 1 started in 2013.
This study's enrollment of 24 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 57 across the 14 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 1, and was the 10th registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing faricimab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single doses
Drug: RO6867461
Multiple doses
Drug: RO6867461
Single or multiple ascending dose by intravitreal injection
Ocular safety, assessed by BCVA (EDTRS chart), slitlamp examination, ophthalmoscopy, IOP, fundus photography, SD-OCT, angiography
Time frame: Part A, 12 weeks; Part B, 20 weeks
Safety: Incidence of adverse events
Time frame: Part A, 12 weeks; Part B, 20 weeks
Pharmacokinetics: Area under the concentration time curve (AUC)
Time frame: Part A, 12 weeks; Part B, 20 weeks
Pharmacokinetics: Maximum plasma concentration (Cmax)
Time frame: Part A, 12 weeks; Part B, 20 weeks
The record gives a start of Dec 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab